Open this publication in new window or tab >>Karolinska Inst, Div Expt Canc Med, Dept Lab Med LABMED, SE-14186 Stockholm, Sweden.;Karolinska Univ Hosp Huddinge, Clin Res Ctr, SE-14186 Stockholm, Sweden.;Karolinska Univ Hosp Huddinge, Ctr Allogene Stem Cell Transplantat CAST, SE-14186 Stockholm, Sweden..
Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Pancreat Canc Res Lab, SE-14186 Stockholm, Sweden..
Karolinska Inst, Div Expt Canc Med, Dept Lab Med LABMED, SE-14186 Stockholm, Sweden..
Karolinska Inst, Div Expt Canc Med, Dept Lab Med LABMED, SE-14186 Stockholm, Sweden.;Univ Hamburg, Ctr Hybrid Nanostruct CHyN, D-22607 Hamburg, Germany..
Karolinska Inst, Div Expt Canc Med, Dept Lab Med LABMED, SE-14186 Stockholm, Sweden.;Karolinska Univ Hosp Huddinge, Clin Res Ctr, SE-14186 Stockholm, Sweden.;Karolinska Univ Hosp Huddinge, Ctr Allogene Stem Cell Transplantat CAST, SE-14186 Stockholm, Sweden..
Karolinska Inst, Div Expt Canc Med, Dept Lab Med LABMED, SE-14186 Stockholm, Sweden.;Karolinska Univ Hosp Huddinge, Clin Res Ctr, SE-14186 Stockholm, Sweden.;Karolinska Univ Hosp Huddinge, Ctr Allogene Stem Cell Transplantat CAST, SE-14186 Stockholm, Sweden..
KTH, School of Engineering Sciences (SCI), Applied Physics, Materials and Nanophysics.
Univ Hamburg, Ctr Hybrid Nanostruct CHyN, D-22607 Hamburg, Germany..
KTH. Alexandria Univ, Inst Grad Studies & Res IGSR, Alexandria 21526, Egypt..
Karolinska Inst, Div Expt Canc Med, Dept Lab Med LABMED, SE-14186 Stockholm, Sweden.;Karolinska Univ Hosp Huddinge, Clin Res Ctr, SE-14186 Stockholm, Sweden.;Karolinska Univ Hosp Huddinge, Ctr Allogene Stem Cell Transplantat CAST, SE-14186 Stockholm, Sweden.;Alexandria Univ, Inst Grad Studies & Res IGSR, Alexandria 21526, Egypt..
Show others...
2020 (English)In: ACS Applied Materials and Interfaces, ISSN 1944-8244, E-ISSN 1944-8252, Vol. 12, no 48, p. 53665-53681Article in journal (Refereed) Published
Abstract [en]
Late diagnosis and refractory behavior toward current treatment protocols make pancreatic ductal adenocarcinoma (PDAC) one of the most difficult cancer forms to treat. The imaging-based approach plays an important role to identify potentially curable PDAC patients in high-risk groups at the early stage. In the present study, we developed a core-shell structured gold nanorod (AuNR) as a contrast agent for multimodal imaging and investigated its application for PDAC diagnosis. The composite nanopartides composed of a AuNR core inside a layer of mesoporous silica that was then coated with a gadolinium oxide carbonate shell (AuNR-SiO2 -Gd) are designed to be used in magnetic resonance imaging (MRI), X-ray computed tomography (CT), and photoacoustic imaging (PM). A phantom study with the AuNR-SiO2-Gd NPs demonstrated higher MRI contrast compared to Gadovist and higher X-ray attenuation than Visipaque. A strong, stable, and broad wavelength range signal with a peak at 800 nm was observed in PAI. The AuNR-SiO2-Gd NPs showed significant contrast enhancement under PAI/MRI/CT in both the liver and spleen of control mice after intravenous administration. The utility in PDAC was studied in a genetically engineered mouse model carrying Kras and p53 mutations, which develops spontaneous tumors and keeps the desmoplasia and hypovascularity feature of PDAC in patients. The AuNR-SiO2-Gd NPs were highly accumulated in the surrounding soft tissues but were sparsely distributed throughout the tumor due to dense stroma infiltration and poor tumor vascularization. Hence, a negative contrast within the tumor area in CT/PAI and a positive contrast in MRI were observed. In conclusion, AuNR-SiO2-Gd NPs have good potential to be developed as a multimodal contrast agent for PDAC, which might improve early diagnosis and benefit the clinical outcome for PDAC patients.
Place, publisher, year, edition, pages
American Chemical Society (ACS), 2020
Keywords
multimodal, magnetic resonance imaging, computed tomography, photoacoustic imaging, pancreatic ductal adenocarcinoma
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:kth:diva-289087 (URN)10.1021/acsami.0c15430 (DOI)000596876400009 ()33201660 (PubMedID)2-s2.0-85096661158 (Scopus ID)
Note
QC 20210125
2021-01-252021-01-252022-06-25Bibliographically approved